Merck: research agreement in AI with Absci
(CercleFinance.com) - US-based Absci Corporation announced on Friday that it has sruck a research agreement with Merck to develop an artificial intelligence platform for drug discovery.
Under the terms of the collaboration, Absci will use its non-standard amino acid technology, called "Bionic Protein", to provide Merck with enzymes that can be used in its biomanufacturing processes.
The agreement will trigger an immediate milestone payment, along with other payments, to Absci.
Merck, in turn, will have the option to select up to three targets from their collaboration agreement and enter into a drug development partnership.
Copyright (c) 2022 CercleFinance.com. All rights reserved.